These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 14726470)
1. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Hafner C; Schmitz G; Meyer S; Bataille F; Hau P; Langmann T; Dietmaier W; Landthaler M; Vogt T Clin Chem; 2004 Mar; 50(3):490-9. PubMed ID: 14726470 [TBL] [Abstract][Full Text] [Related]
2. Compartmentalized Eph receptor and ephrin expression in the thymus. Vergara-Silva A; Schaefer KL; Berg LJ Gene Expr Patterns; 2002 Dec; 2(3-4):261-5. PubMed ID: 12617812 [TBL] [Abstract][Full Text] [Related]
3. Ephrin A receptors and ligands in lesions and normal-appearing white matter in multiple sclerosis. Sobel RA Brain Pathol; 2005 Jan; 15(1):35-45. PubMed ID: 15779235 [TBL] [Abstract][Full Text] [Related]
4. Integration of cancer-related genetic landscape of Eph receptors and ephrins with proteomics identifies a crosstalk between EPHB6 and EGFR. Hanover G; Vizeacoumar FS; Banerjee SL; Nair R; Dahiya R; Osornio-Hernandez AI; Morales AM; Freywald T; Himanen JP; Toosi BM; Bisson N; Vizeacoumar FJ; Freywald A Cell Rep; 2023 Jul; 42(7):112670. PubMed ID: 37392382 [TBL] [Abstract][Full Text] [Related]
5. Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics. Liu J; Yuan Q; Chen X; Yang Y; Xie T; Zhang Y; Qi B; Li S; Shang D Sci Rep; 2024 Jul; 14(1):17650. PubMed ID: 39085301 [TBL] [Abstract][Full Text] [Related]
6. Engineered Recombinant EGFP-Azurin Theranostic Nanosystem for Targeted Therapy of Prostate Cancer. Bhardwaj R; Mishra P Mol Pharm; 2023 Dec; 20(12):6066-6078. PubMed ID: 37906960 [TBL] [Abstract][Full Text] [Related]
13. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683 [TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188 [TBL] [Abstract][Full Text] [Related]
15. Effect of EPH-ephrin signaling on the growth of human leukemia cells. Takahashi Y; Itoh M; Nara N; Tohda S Anticancer Res; 2014 Jun; 34(6):2913-8. PubMed ID: 24922654 [TBL] [Abstract][Full Text] [Related]
16. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. Falivelli G; Lisabeth EM; Rubio de la Torre E; Perez-Tenorio G; Tosato G; Salvucci O; Pasquale EB PLoS One; 2013; 8(11):e81445. PubMed ID: 24348920 [TBL] [Abstract][Full Text] [Related]
17. High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Lu CY; Yang ZX; Zhou L; Huang ZZ; Zhang HT; Li J; Tao KS; Xie BZ Oncol Rep; 2013 Nov; 30(5):2179-86. PubMed ID: 23970317 [TBL] [Abstract][Full Text] [Related]
18. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3. Lahtela J; Corson LB; Hemmes A; Brauer MJ; Koopal S; Lee J; Hunsaker TL; Jackson PK; Verschuren EW Cell Cycle; 2013 Feb; 12(4):625-34. PubMed ID: 23324396 [TBL] [Abstract][Full Text] [Related]
19. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Lisabeth EM; Fernandez C; Pasquale EB Biochemistry; 2012 Feb; 51(7):1464-75. PubMed ID: 22242939 [TBL] [Abstract][Full Text] [Related]